HiberCell is a biotechnology company that develops therapeutics for the prevention of relapse and metastasis. It is a company that focuses exclusively on therapeutically modulating the biology and mechanisms of tumor dormancy. The company is developing therapeutics that target dormant disseminated tumor cells from solid and liquid cancers and the company has the goal of preventing or delaying the recurrence of cancer.
The company was launched based on the research that was carried out at Mount Sinai’s Tisch Cancer Institute which shows that cancer recurrence is driven by dormant disseminated tumor cells, or DTCs, that can persist in the body for long period of time. The company aims to approach cancer as a systemic disease, detect and target DTCs to prevent or delay metastasis.
HiberCell is committed to developing therapeutic molecules that overcome foundational scientific barriers which prevent patients from living longer and ensure people live cancer-free. HiberCell has a multidisciplinary team that consists of cancer scientists, drug developers and venture capitalists who are leaders in their respective fields.